Your browser doesn't support javascript.
loading
Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Morvan, Frederic; Rondeau, Jean-Michel; Zou, Chao; Minetti, Giulia; Scheufler, Clemens; Scharenberg, Meike; Jacobi, Carsten; Brebbia, Pascale; Ritter, Veronique; Toussaint, Gauthier; Koelbing, Claudia; Leber, Xavier; Schilb, Alain; Witte, Florian; Lehmann, Sylvie; Koch, Elke; Geisse, Sabine; Glass, David J; Lach-Trifilieff, Estelle.
Afiliação
  • Morvan F; MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • Rondeau JM; Chemical Biology and Therapeutics, Structural Biophysics Group, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • Zou C; Chemical Biology and Therapeutics, Structural Biophysics Group, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • Minetti G; MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • Scheufler C; Chemical Biology and Therapeutics, Structural Biophysics Group, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • Scharenberg M; Novartis Biologics Center, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • Jacobi C; MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • Brebbia P; MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • Ritter V; MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • Toussaint G; MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • Koelbing C; MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • Leber X; Novartis Biologics Center, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • Schilb A; MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • Witte F; MorphoSys AG, 82152 Martinsried/Planegg, Germany.
  • Lehmann S; Chemical Biology and Therapeutics, Structural Biophysics Group, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • Koch E; Chemical Biology and Therapeutics, Structural Biophysics Group, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • Geisse S; Novartis Biologics Center, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • Glass DJ; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139.
  • Lach-Trifilieff E; MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland; estelle.trifilieff@novartis.com.
Proc Natl Acad Sci U S A ; 114(47): 12448-12453, 2017 11 21.
Article em En | MEDLINE | ID: mdl-29109273
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Músculo Esquelético / Anticorpos Bloqueadores / Receptores de Activinas Tipo II / Hipertrofia / Anticorpos Monoclonais Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Músculo Esquelético / Anticorpos Bloqueadores / Receptores de Activinas Tipo II / Hipertrofia / Anticorpos Monoclonais Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article